(RTTNews) - Repligen Corp. (RGEN), a bioprocessing company, on Friday announced agreements to issue $1 billion in 0.25% convertible senior notes due 2031.

Repligen Announces $1 Bln Convertible Notes Offering To Extend Debt Maturity 

Repligen Corporation reported its financial results for the third quarter ended September 30, 2026, with reported revenue of $209 million, representing a year-over-year increase of 11% as reported and 12.5% organic. Under GAAP, the company recorded a loss from operations of $29.5

Repligen Corporation Reports Third Quarter 2026 Revenue of $209 million

(RTTNews) - Repligen Corp. (RGEN), a life sciences company, announced that it has completed the previously announced acquisition of BioLife Solutions, Inc. (BLFS), a developer and supplier of cell processing tools and services for the cell and gene therapy market.

Repligen Corp Completes Acquisition Of BioLife Solutions 

Key PointsIt'll replace a healthcare company that's being acquired.

Why Freshworks Stock Bumped Higher Today

REPLIGEN CORP filed a 425

Shares of Kodiak Sciences, Repligen, and Biogen surged to annual highs amid positive company catalysts.

Why Did KOD, RGEN, BIIB Stocks Rise To 52-Week Highs?

Repligen Corporation, a life sciences company, develops and commercializes bioprocessing technologies and systems in North America, Europe, the Asia Pacific, and internationally. The company's products include hollow fiber consumables, KRM chromatography system, resins for new modalities, PATsmart MAVERICK and PATsmart MAVEN for real-time monitoring and control of critical bioprocess parameters, PATsmart REBEL, an at-line cell culture media analyzer; and PATsmart ZipChip, a high-resolution sample separations device, PATsmart SoloVPE slope spectroscopy system, and SoloVPE PLUS System. It offers Protien A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company also provides chromatography products, including OPUS pre-packed chromatography columns, which are used in the purification and quality control of biological drugs, as well as ELISA test kits. In addition, it offers filtration products, such as XCell ATF Cell Retention Systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems. The company offers its products under the OPUS, XCell, XCell ATF, TFDF, KrosFlo, SIUS, ProConnex, Spectra/Por, NGL-Impact, SoloVPE, FlowVPE, RPM, XO, Metenova MixOne, and AVIPure and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has a collaboration agreement with Navigo Proteins GmbH to develop multiple affinity ligands. The company was incorporated in 1981 and is headquartered in Waltham, Massachusetts.

Repligen Corporation News